Tesamorelin : the approved GHRH analogue against visceral fat

The GHRH axis and GH secretion

Tesamorelin belongs to the family of GHRH analogues, like CJC-1295. To understand its specific interest, let's recall the architecture of the somatotropic axis:

• The hypothalamus pulses the GHRH (29–44 amino acids) to the anterior pituitary gland every 3 to 5 hours
• The pituitary somatotroph cells respond by releasing the GH (somatotropin) in traffic
• GH stimulates hepatic synthesis ofIGF-1, the main mediator of metabolic and anabolic effects
• Negative feedback via the somatostatin limits the amplitude of the pulses

Native GHRH has an extremely short plasma half-life (< 7 minutes) due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at the Tyr¹-Ala² position. Tesamorelin contains a modification trans-3-hexadecenoic at the N-terminal end which protects this cleavage site while maintaining full agonist activity of the GHRH-R receptor.

Mechanism of action: Pulsatile GH and lipolysis

Physiological activation

Unlike very long-acting analogues (CJC-1295 with DAC, half-life 6–8 days), Tesamorelin maintains a GH secretion profile physiological pulsatileIt amplifies the amplitude of existing GH pulses rather than causing a continuous tonic rise. This distinction is important because pulsatility preserves the sensitivity of GH receptors and prevents desensitization.

From GH to visceral lipolysis

Growth hormone (GH) stimulated by Tesamorelin acts directly on adipocytes via its own receptors (GHR), activating hormone-sensitive lipase (HSL) and inhibiting lipoprotein lipase (LPL). Visceral fat (deep intra-abdominal deposits) expresses more GH receptors and is therefore more concentrated there. more sensitive to GH-induced lipolysis than subcutaneous fat — which explains the selective effectiveness of Tesamorelin on this compartment.

Clinical data: pivotal studies

Background: lipoatrophy under HAART treatment

The strongest clinical data concern HIV-positive patients on highly active antiretroviral therapy (HAART), who frequently develop visceral fat accumulation (central lipohypertrophy). Two randomized phase 3 trials led to FDA approval in 2010.

Effects measured beyond visceral fat

Clinical studies report favorable side effects consistent with the elevation of GH/IGF-1:

• Lipid profile : reduction of serum triglycerides in several cohorts
• Inflammatory markers : tendency towards a reduction in CRP and IL-6 (correlated with VAT loss)
• IGF-1 : reproducible increase of 70–120% compared to baseline under 2–4 mg/day
• Body composition : maintenance or slight increase of lean mass

Tesamorelin vs other GHRH analogues

Impact on the IGF-1 axis

IGF-1 (Insulin-like Growth Factor-1) is the main peripheral effector of GH. Tesamorelin induces a dose-dependent increase in serum IGF-1, which is an indirect biomarker of stimulated GH activity. In clinical trials, patients receiving 2 mg/day achieved IGF-1 levels comparable to the upper range of normal for their age—without exceeding the pathological values associated with acromegaly.

Research protocols

Dosage observed in studies

The FDA-approved protocol for HIV lipoatrophy is 2 mg by subcutaneous injection once a day, at the abdominal level, in the evening before bedtime (to coincide with the physiological nocturnal GH pulse). Some research protocols use fractionated doses (1 mg twice daily) to maintain more consistent GHRH-R coverage while preserving pulsatility.

Reconstruction

Tesamorelin is available in lyophilized form and must be reconstituted with bacteriostatic water (BAC water with 0.9% benzyl alcohol). For a 2 mg vial reconstituted in 2 mL of BAC water, the concentration is 1 mg/mL. See our reconstruction guide for the detailed protocol.

Stability after reconstitution

The reconstituted product must be stored between 2 and 8°C (refrigerated) and used within 21 days. Avoid freezing the reconstituted solution. The unreconstituted lyophilized vial can be stored at room temperature below 25°C or in a refrigerator, protected from light.

Security Profile

In phase 3 studies, the tolerability profile of Tesamorelin was considered acceptable. The most frequent adverse events (>5%) included injection site reactions (erythema, pruritus, mild pain), transient fluid retention, and mild arthralgia and myalgia. These effects are consistent with those observed with low-dose exogenous GH and tend to resolve after the first few weeks.

Technical specifications